SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Frostman who wrote (577)10/5/1997 9:44:00 AM
From: durkin   of 23519
 
Vivus is doing a smart initiative in their upcoming road shows or presentations to analyst to increase Wall Street visiblily of the Company. They are obviously intelligent enough to know that the major brokerage houses will not pick them up do to small # of shares outstanding and the limited float. The only way to attract the big house analyst i.e. Merrill Lynch, Morgan Stanley, Dean Witter, and Solomon Smith Barney, (all with over 10,000 retail brokers) is to have another stock split. Remember the last one was announced in the 45-50 range. If one or two of these major firms starts coverage with a buy rating you will unequivacably see a dramatic price increase followed by one of the biggest short squeezed ever recorded. Based on 98 earnings estimate of 1.40 - 2.00 per share I think the stock is extremely undervalued. Because the company is currently quadrupling its production capacity I think only a 100% earnings increase might prove to be conservative. Looking out 6 months from now we will be getting 99 EPS estimates. These will probably be in the 2.50 - 3.50 range. I think this company will be a good hold for the next 12-36 months.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext